GlucoModicum
GlucoModicum is a Finnish health technology company that develops Sofio™, the world's first needle-free glucose monitoring sensor using magneto-hydrodynamic (MHD) technology, serving people with diabetes and healthcare providers globally.
- Company typePrivate
- Founded2018
- HeadquartersHelsinki, Finland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GlucoModicum does
GlucoModicum is a Finnish health technology company founded in 2018 and headquartered in Helsinki, developing Sofio™, a needle-free continuous glucose monitoring sensor based on proprietary magneto-hydrodynamic (MHD) technology. The device draws a micro-sample through the skin without needles, enabling single-day glucose monitoring for people with diabetes, and has been validated in clinical studies involving over 2,000 participants. The technology represents a first-in-class architectural departure from existing needle-based CGM approaches, directly addressing pain, discomfort, and compliance barriers associated with traditional glucose monitoring.
The company has partnered with Mpac Lambert to design and build an automated manufacturing line capable of sub-second cycle times with an initial annual capacity of 21 million units, expandable through additional modules. This two-year industrial proof-of-principle effort positions GlucoModicum to transition from lab-scale demonstration to commercial production for global distribution. Sofio was unveiled in December 2025 in Helsinki, with the manufacturing partnership formalised in January 2026.
GlucoModicum operates a hardware-based B2B medical device business model, targeting healthcare providers and patients with diabetes globally. Revenue is expected to be generated through sales of the Sofio device enabled by its global distribution partnership, though specific pricing, customer relationships, and revenue figures are not publicly disclosed. The company is led by co-founders Alejandro García Pérez (CTO) and Jokke Mäki (Managing Director), with disclosed funding of approximately $3 million from the European Innovation Council in 2021.
GlucoModicum firmographics
Firmographics- Name
- GlucoModicum
- Legal name
- GlucoModicum
- Website
- https://glucomodicum.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GlucoModicum is a Finnish health technology company that develops Sofio™, the world's first needle-free glucose monitoring sensor using magneto-hydrodynamic (MHD) technology, serving people with diabetes and healthcare providers globally.
- Ownership category
- akta.pro rank
GlucoModicum industry classification
Industry- Product category
- Continuous Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
Keywords
Where GlucoModicum is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
GlucoModicum business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Sofio Device Sales: Revenue generated from the sale of the Sofio needle-free glucose monitoring sensor, a medical device for single-day glucose monitoring. The manufacturing partnership with Mpac Lambert enables commercial-scale production for global distribution.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
GlucoModicum product offering
Product offeringCore offering
GlucoModicum develops and manufactures Sofio, a needle-free continuous glucose monitoring sensor that uses proprietary magnetohydrodynamic (MHD) technology to draw a micro-sample through the skin and enable single-day glucose monitoring. The device is targeted at people with diabetes and is produced via an automated manufacturing line (built with partner Mpac Lambert) with an initial capacity of 21 million units per year for global commercial distribution.
Product overview
GlucoModicum is a Finnish health technology company that offers a single unified product: Sofio™, the world's first needle-free glucose monitoring sensor. Sofio™ uses proprietary magneto-hydrodynamic (MHD) technology to draw micro-samples through the skin without needles, enabling non-invasive single-day glucose monitoring. The product is produced via an automated manufacturing line developed with partner Mpac Lambert, with an initial capacity of approximately 21 million units per year.
Differentiator
Problem solved
Functional benefit
Brands
- Sofio: The world's first needle-free glucose monitoring device using magnetohydrodynamic (MHD) technology that measures glucose levels by drawing a micro-sample through the skin without needles.
Products and services
- Sofio
Companies that use GlucoModicum
Customer profileSegments2 records
Ideal customer profiles2 records
GlucoModicum technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
GlucoModicum partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mpac LambertcoreMpac Lambert partnered with GlucoModicum to design and build a first-of-its-kind automated manufacturing line for Sofio, GlucoModicum's needle-free glucose monitoring sensor. The production system achieves sub-second cycle times with an initial capacity of 21 million units per year and can be expanded by adding additional modules. The collaboration aims to transition Sofio from lab-scale demonstration to commercial production for global distribution, making needle-free glucose tracking more widely accessible.
Scale indicators4 records
Recent moves3 records
Expansion highlights4 records
GlucoModicum competitors and assessment
Company assessmentEmerging players
- Senseonics: Markets Eversense, the only long-term implantable CGM (180-day sensor). Comparable as a smaller-cap glucose monitoring innovator with a differentiated architecture targeting the same diabetes patient population.
- Know Labs: Developing a non-invasive, radio-frequency-based glucose monitor (KnowU). Closely comparable to GlucoModicum as an emerging player pursuing needle-free / non-invasive glucose measurement using a fundamentally different physical mechanism.
- LifePlus: Developing a non-invasive continuous glucose monitoring wearable (Lief). Comparable as an emerging player in needle-free CGM, though at an earlier commercial stage than GlucoModicum.
- Afon Technology: Early-stage UK developer of a non-invasive, wearable continuous blood glucose monitor. Comparable as an emerging player in needle-free / non-invasive glucose sensing targeting the same diabetes use case as GlucoModicum's Sofio.
- Metamaterial Inc. Developing meta-optical sensing technology including non-invasive glucose monitoring applications. Comparable as an emerging player exploring novel physical mechanisms for glucose/biomarker sensing, with overlapping R&D ambition though a different sensing modality.
Direct peers
- Dexcom: Global market leader in continuous glucose monitoring (CGM) sensors (G6, G7). Directly comparable as a CGM device maker targeting diabetes patients and clinicians, though GlucoModicum's needle-free MHD approach is a category-defining differentiation rather than a like-for-like device.
Broad incumbents
- Roche Diabetes Care: Major incumbent in blood glucose monitoring (Accu-Chek) historically dominant in BGM strips and now expanding into CGM. Comparable as a broad incumbent in glucose monitoring devices serving diabetes patients worldwide.
- Ascensia Diabetes Care: Spun out of Bayer Diabetes Care, markets the CONTOUR line of blood glucose meters. Comparable as an established glucose monitoring incumbent with global distribution, though focused on BGM strips rather than needle-free CGM.
- Medtronic: Sells the Guardian CGM system alongside its insulin pump portfolio (MiniMed). Comparable as a major medtech incumbent in diabetes care devices, with overlapping customers (endocrinologists and insulin-using patients) but a much wider product portfolio.
- Abbott: Markets the FreeStyle Libre family of CGM sensors, the dominant global CGM franchise by volume. Comparable as a glucose monitoring medical device incumbent serving people with diabetes, though Abbott is a diversified diagnostics and devices giant with a much broader portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
GlucoModicum social profiles
Digital presenceGlucoModicum financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlucoModicum leadership team
Management profileNumber of profiles
Profiles2 records
GlucoModicum funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlucoModicum M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlucoModicum
What does GlucoModicum do?
GlucoModicum develops and manufactures Sofio, a needle-free continuous glucose monitoring sensor that uses proprietary magnetohydrodynamic (MHD) technology to draw a micro-sample through the skin and enable single-day glucose monitoring. The device is targeted at people with diabetes and is produced via an automated manufacturing line (built with partner Mpac Lambert) with an initial capacity of 21 million units per year for global commercial distribution.
Is GlucoModicum a public or private company?
GlucoModicum is a private company. It is classified as venture growth investor backed and is currently operating.
When was GlucoModicum founded?
GlucoModicum was founded in 2018. It employs 11 to 50 people.
Where is GlucoModicum based?
GlucoModicum is headquartered in Helsinki, Finland, in the Europe region.
How does GlucoModicum make money?
One revenue line is on record: sofio Device Sales.
Who are GlucoModicum's main competitors?
Emerging players on record are Senseonics, Know Labs, LifePlus, Afon Technology and Metamaterial Inc.. Dexcom is listed as a direct peer. Broad incumbents are Roche Diabetes Care, Ascensia Diabetes Care, Medtronic and Abbott.
Does GlucoModicum have an API?
No public API is recorded for GlucoModicum.
What industry is GlucoModicum in?
GlucoModicum's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 334510 and its SIC code is 3845.